Sequence: CRGDKGPDC
| Experiment Id | EXP001787 |
|---|---|
| Paper | Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC- |
| Peptide | CC9 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | CC9 co-administered/combined with PC/miR-34a complexes (concentration not explicitly stated for in vivo; optimized at 20 µM for in vitro) |
| Rna Concentration | miR-34a 15 µM in injection solution; 20 µg per dose (100 µL) |
| Mixing Ratio | N/P = 30; CC9 added post-complexation |
| Formulation Format | PC/miRNA polyplex with co-administered CC9 (physical combination) for systemic tumor therapy |
| Formulation Components | PC/miR-34a polyplex (N/P 30) with free CC9 added (PC/miR-34a + CC9; CC9 20 µM used in vitro optimization) administered IV to PANC-1 xenograft mice |
| Size Nm | 261.00 |
| Zeta Mv | 16.50 |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c athymic female mice bearing subcutaneous PANC-1 xenografts |
| Administration Route | Intravenous injection (100 µL); twice per week for 2 weeks; dose miR-34a 20 µg per injection |
| Output Type | In vivo antitumor efficacy and tumor apoptosis |
| Output Value | Tumor growth strongly inhibited (tumor volumes <100 mm3); increased TUNEL-positive cells; tumor miR-34a upregulated; Bcl-2/cyclin D1 reduced |
| Output Units | |
| Output Notes | Tumor targeting and penetration attributed to CC9 (RGD motif + proteolytic cleavage to CRGDK with neuropilin-1 binding). |
| Toxicity Notes | No major systemic toxicity described in the paper. |
| Curation Notes |